MannKind Corp. Stock
Price
Target price
€2.94
€2.94
-33.810%
-1.589
-33.810%
€8.59
25.02.26 / Tradegate
WKN: A2DMZL / Symbol: MNKD / Name: MannKind / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
MannKind Corp. Stock
MannKind Corp. took a tumble today and lost -€1.589 (-33.810%).
The stock is an absolute favorite of our community with 24 Buy predictions and no Sell predictions.
Based on the current price of 2.94 € the target price of 8 € shows a potential of 171.74% for MannKind Corp. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for MannKind Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of MannKind Corp. in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of MannKind Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| MannKind Corp. | -33.810% | -36.180% | -36.318% | -45.156% | -40.308% | -42.657% | -36.236% |
| Biocryst Pharmaceuticals | -1.920% | 3.665% | 11.204% | -18.883% | -2.502% | -25.950% | -25.709% |
| Heron Therapeutics Inc. | 6.950% | -10.600% | -27.845% | -44.230% | -19.749% | -58.544% | -93.972% |
| Madrigal Pharmaceuticals inc. | -1.660% | -11.652% | -9.393% | 25.170% | -26.078% | 40.649% | 264.671% |
Comments
MannKind (MNKD) had its "buy" rating reaffirmed by HC Wainwright. They now have a $11.00 price target on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Show more
Ratings data for MNKD provided by MarketBeat
News
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares?
On Dec. 17, 2025, Michael Castagna, Chief Executive Officer of MannKind Corporation (NASDAQ:MNKD), executed an exercise and immediate sale of 65,804 common shares for a transaction value of
